Cameron Turtle insider trades
Open-market stock purchases and sales by Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc, from SEC Form 4 filings since Nov 30, 2018.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $216K |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $732K |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $326K |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $35.6K |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $75.2K |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $681K |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $541K |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $135K |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $1.6K |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $247K |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $575K |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $235K |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $369K |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $255K |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $71.8K |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $227K |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $126K |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $22.5K |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $607K |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $133K |
| Mar 23, 2026 | DMRA Damora Therapeutics, Inc | Bought (not open market) | — |
| Mar 2, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $246K |
| Mar 2, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $387K |
| Feb 2, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $30.5K |
| Feb 2, 2026 | SYRE Spyre Therapeutics, Inc | Sold | $462K |
Companies traded
- SYRE Spyre Therapeutics, Inc: 31 sales, last Sep 1, 2026
- DMRA Damora Therapeutics, Inc: other filings, last Mar 23, 2026
- ORKA Oruka Therapeutics, Inc: other filings, last Jun 2, 2025
- AGLE Spyre Therapeutics, Inc: other filings, last Nov 24, 2023
- EIDX Eidos Therapeutics, Inc: 30 sales, last Jan 26, 2021
- BBIO BridgeBio Pharma, Inc: 17 sales, last Dec 28, 2020